Details

Autor(en) / Beteiligte

• Somers, Judith A.E
• Brand, Anneke
• van Hensbergen, Yvette
• Mulder, Arend
• Oudshoorn, Machteld
• Sintnicolaas, Kees
• Gratama, Jan-Willem
• Falkenburg, J.H. Frederik
• Braakman, Eric
• Cornelissen, Jan J

Titel

Double Umbilical Cord Blood Transplantation: A Study of Early Engraftment Kinetics in Leukocyte Subsets using HLA-Specific Monoclonal Antibodies

Ist Teil von

• Biology of blood and marrow transplantation, 2013-02, Vol.19 (2), p.266-273

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2013

Quelle

Elektronische Zeitschriftenbibliothek - Freely accessible e-journals

Beschreibungen/Notizen

• Abstract Single cord blood unit (CBU) predominance is usually established within the first month after double umbilical cord blood transplantation (UCBT). However, the kinetics of engraftment of the different leukocyte subsets and the mechanism of graft predominance is largely unknown. To investigate whether a differential engraftment might reveal a specific subset that could play a key role in the mechanism of graft predominance, we studied early engraftment kinetics of different leukocyte subpopulations by flow cytometry using human monoclonal antigen–specific human leukocyte antigen antibodies, directed against mismatched human leukocyte antigen-A or –B antigens between recipient and CBUs. Twenty-two patients, who had received a double UCBT preceded by a reduced-intensity conditioning regimen, were evaluated at days +11, +18, +25, and +32 posttransplantation. Single CBU predominance in the various leukocyte subsets was established within 18 days posttransplantation. CD4+ T cells of the dominant CBU showed early peripheral blood expansion. Moreover, chimerism in CD4+ and CD8+ T cell and natural killer cell subsets at day +11 was predictive of ultimate graft predominance. These findings show that engraftment kinetics of the various leukocyte subsets vary considerably after double UCBT and may suggest an important role for CD4+ T cells in a presumed alloreactive graft-versus-graft rejection.